Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(0.91) per share. This is a 152.78 percent decrease over losses of $(0.36) per share from the same period last year.
Blood-Based Colorectal Cancer CRC Screening Market Likely to Benefit From FDA’s Panel Surprise Advisory Possibility: Analyst
Tuesday, Guardant Health Inc (NASDAQ: GH) announced that the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the premarket approval application (PMA) for its Shield blood test to screen for colorectal
